Alvotech, Teva Pharmaceuticals and FDA
Alvotech and Teva Pharmaceuticals announce FDA accepts Biologics License Application for AVT06
Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT06, Alvotech’s proposed biosimilar to Eylea (aflibercept) 2 mg.
Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric ...
U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...
Teva CEO Richard Francis said that he had not expected such a harsh reaction from the market but he sees a positive side to ...
In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...
Teva has not raised capital since it acquired Actavis from Allergan in 2016 - a deal worth nearly $40 billion and for which ...
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
Axsome Therapeutics gained more than $1 billion in market value Monday, after the brain drug developer disclosed a patent ...
Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A copy of the letter can be downloaded here. The fund’s Investor Class (SSHFX) ...
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback